FILIP1L Loss Is a Driver of Aggressive Mucinous Colorectal Adenocarcinoma and Mediates Cytokinesis Defects through PFDN1.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 11 2021
Historique:
received: 19 03 2021
revised: 25 06 2021
accepted: 17 08 2021
pubmed: 22 8 2021
medline: 12 1 2022
entrez: 21 8 2021
Statut: ppublish

Résumé

Aneuploid mucinous colorectal adenocarcinoma (MAC) is an aggressive subtype of colorectal cancer with poor prognosis. The tumorigenic mechanisms in aneuploid MAC are currently unknown. Here we show that downregulation of Filamin A-interacting protein 1-like (FILIP1L) is a driver of MAC. Loss of FILIP1L increased xenograft growth, and, in colon-specific knockout mice, induced colonic epithelial hyperplasia and mucin secretion. The molecular chaperone prefoldin 1 (PFDN1) was identified as a novel binding partner of FILIP1L at the centrosomes throughout mitosis. FILIP1L was required for proper centrosomal localization of PFDN1 and regulated proteasome-dependent degradation of PFDN1. Importantly, increased PFDN1, caused by downregulation of FILIP1L, drove multinucleation and cytokinesis defects

Identifiants

pubmed: 34417201
pii: 0008-5472.CAN-21-0897
doi: 10.1158/0008-5472.CAN-21-0897
pmc: PMC8563430
mid: NIHMS1735936
doi:

Substances chimiques

Biomarkers, Tumor 0
FILIP1L protein, human 0
Intracellular Signaling Peptides and Proteins 0
Molecular Chaperones 0
prefoldin 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

5523-5539

Subventions

Organisme : NCI NIH HHS
ID : P30 CA072720
Pays : United States

Informations de copyright

©2021 The Authors; Published by the American Association for Cancer Research.

Références

Cancer Res. 1999 Nov 1;59(21):5438-42
pubmed: 10554013
Nat Cell Biol. 2009 Aug;11(8):994-1001
pubmed: 19620968
Nat Cell Biol. 2010 Nov;12(11):1035-45
pubmed: 20890297
Genes Dev. 2008 Jan 1;22(1):91-105
pubmed: 18086858
Dev Biol. 2008 Jan 1;313(1):320-34
pubmed: 18062952
Nat Methods. 2007 Apr;4(4):359-65
pubmed: 17396127
J Histochem Cytochem. 1999 Aug;47(8):1063-74
pubmed: 10424891
Gut. 2004 Aug;53(8):1137-44
pubmed: 15247181
Mol Biol Cell. 2005 Dec;16(12):5857-65
pubmed: 16221885
J Am Soc Nephrol. 2009 Jul;20(7):1444-52
pubmed: 19497970
Br J Cancer. 1993 May;67(5):1042-6
pubmed: 8507281
Dev Cell. 2014 Oct 27;31(2):171-87
pubmed: 25307480
Oncotarget. 2015 Sep 22;6(28):25715-25
pubmed: 26329972
Eur J Surg. 1999 Apr;165(4):363-8
pubmed: 10365839
Am J Pathol. 2013 Aug;183(2):493-503
pubmed: 23769888
Chin Med J (Engl). 1992 Mar;105(3):241-6
pubmed: 1395845
Gastroenterology. 2008 Jun;134(7):1950-60, 1960.e1
pubmed: 18435933
Oncogene. 2017 Aug 17;36(33):4750-4766
pubmed: 28394342
Trends Cell Biol. 2011 Dec;21(12):727-35
pubmed: 21782440
Nat Rev Cancer. 2019 Jan;19(1):32-45
pubmed: 30523339
Int J Cancer. 2014 Jul 1;135(1):48-60
pubmed: 24327474
Gut. 2018 Jul;67(7):1229-1238
pubmed: 28642331
MethodsX. 2019 Oct 18;6:2468-2475
pubmed: 31720237
Cancer Res. 2008 Sep 15;68(18):7332-41
pubmed: 18794120
J Cell Biol. 2008 Nov 17;183(4):625-33
pubmed: 19001128
Cell. 2010 May 28;141(5):757-74
pubmed: 20510924
Cell Cycle. 2016 Aug 17;15(16):2124-2134
pubmed: 27294844
Nat Genet. 2007 Nov;39(11):1350-60
pubmed: 17906624
Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5729-34
pubmed: 22451918
Cell Stem Cell. 2010 Feb 5;6(2):175-81
pubmed: 20144789
Cancer Gene Ther. 2014 May;21(5):179-80
pubmed: 24882213
J Cell Biol. 1999 May 3;145(3):481-90
pubmed: 10225950
Gastroenterology. 2011 Sep;141(3):1003-1013.e1-10
pubmed: 21699772
Nat Rev Genet. 2005 Mar;6(3):194-205
pubmed: 15738963
Chromosome Res. 2016 Jan;24(1):105-26
pubmed: 26645976
Dev Cell. 2014 Dec 8;31(5):525-38
pubmed: 25490264
Mod Pathol. 2013 Dec;26(12):1642-56
pubmed: 23807779
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
PLoS Genet. 2015 Nov 03;11(11):e1005638
pubmed: 26528816
Expert Opin Ther Targets. 2014 Dec;18(12):1435-47
pubmed: 25200207
Commun Integr Biol. 2017 Jul 5;10(4):e1338990
pubmed: 28919938
Nat Cell Biol. 2018 Nov;20(11):1303-1314
pubmed: 30361697
Cytogenet Genome Res. 2002;98(1):22-8
pubmed: 12584437
Oncogene. 2004 Nov 18;23(54):8720-30
pubmed: 15480417
Tissue Eng Part C Methods. 2011 Nov;17(11):1097-107
pubmed: 21882900
Nat Cell Biol. 2015 Mar;17(3):241-50
pubmed: 25706235
Nat Rev Clin Oncol. 2016 Jun;13(6):361-9
pubmed: 26323388
Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99
pubmed: 15000151
Histopathology. 2000 Feb;36(2):121-6
pubmed: 10672056
J Biol Chem. 2011 Sep 9;286(36):31397-408
pubmed: 21784850
Oncotarget. 2016 Nov 1;7(44):72229-72241
pubmed: 27750216
Int J Oncol. 2004 Sep;25(3):615-21
pubmed: 15289862
PLoS One. 2013 Dec 05;8(12):e82620
pubmed: 24340050
Curr Biol. 2011 Feb 8;21(3):R126-36
pubmed: 21300279
Chromosome Res. 2016 Jan;24(1):77-91
pubmed: 26700188
Trends Cancer. 2018 Jan;4(1):59-73
pubmed: 29413422
Open Biol. 2014 Jul;4(7):
pubmed: 25008233
Oncogene. 2016 Feb 11;35(6):683-90
pubmed: 25915844
Mol Carcinog. 2009 Jul;48(7):592-8
pubmed: 19123231
EMBO J. 2002 Feb 15;21(4):483-92
pubmed: 11847097
Oncogene. 2010 Apr 1;29(13):1929-40
pubmed: 20062083
Nat Cell Biol. 2001 Apr;3(4):433-8
pubmed: 11283620
Oncotarget. 2016 Nov 22;7(47):77052-77070
pubmed: 27776341
Tissue Cell. 2011 Jun;43(3):201-6
pubmed: 21470648
Bio Protoc. 2012 Feb 10;2(22):
pubmed: 27148556
Int J Cancer. 2006 Apr 1;118(7):1721-7
pubmed: 16231316
Oncogene. 2018 Aug;37(33):4518-4533
pubmed: 29743597
Med Oncol. 2015 Dec;32(12):264
pubmed: 26553318
J Mol Biol. 2000 Feb 25;296(3):757-68
pubmed: 10677279
Nat Commun. 2017 Dec 21;8(1):2238
pubmed: 29269828
Elife. 2019 Feb 13;8:
pubmed: 30758285
Science. 1989 Apr 14;244(4901):207-11
pubmed: 2565047
Nature. 2017 Nov 16;551(7680):333-339
pubmed: 29144463
EMBO J. 2007 Mar 21;26(6):1487-98
pubmed: 17318179
J Cell Biol. 2007 Sep 24;178(7):1109-20
pubmed: 17893240
Sci Rep. 2016 Mar 30;6:23735
pubmed: 27025979
Nat Cell Biol. 2001 Apr;3(4):429-32
pubmed: 11283619
Oncogene. 2017 Feb 16;36(7):885-898
pubmed: 27694898
Dev Cell. 2005 Aug;9(2):223-36
pubmed: 16054029
Oncogene. 2013 Sep 26;32(39):4602-13
pubmed: 23108400
Mol Cancer Res. 2011 Aug;9(8):1126-38
pubmed: 21693594
Nat Genet. 2006 Jul;38(7):787-93
pubmed: 16804544
Cancers (Basel). 2020 Mar 11;12(3):
pubmed: 32168759
Chromosome Res. 2016 Jan;24(1):67-76
pubmed: 26615533
Sci Rep. 2016 Jun 06;6:27401
pubmed: 27264542
Genome Biol. 2006;7(10):R100
pubmed: 17076895

Auteurs

Mijung Kwon (M)

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

Genesaret Rubio (G)

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

Nicholas Nolan (N)

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

Peter Auteri (P)

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

Jean Arly Volmar (JA)

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

Asha Adem (A)

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

Parisa Javidian (P)

Department of Pathology, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey.

Zhongren Zhou (Z)

Department of Pathology, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey.

Michael P Verzi (MP)

Department of Genetics, Rutgers University, Piscataway, New Jersey.

Sharon R Pine (SR)

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
Department of Pharmacology and Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey.

Steven K Libutti (SK)

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey. steven.libutti@cinj.rutgers.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH